
Opinion|Videos|December 25, 2024
Exploring Second-Line Treatments for PBC
Panelists discuss how some patients with primary biliary cholangitis (PBC) have an inadequate response to ursodeoxycholic acid and require second-line treatments, with options including obeticholic acid, seladelpar, and elafibranor, which improve bile acid homeostasis and reduce inflammation.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How often do patients require second-line treatments for PBC, and what agents are available for second-line management?
- How do the mechanisms of action differ between seladelpar, elafibranor, and obeticholic acid?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Controversial 340B Rebate Pilot Program Is Moving Forward
2
Researchers Identify Key Lipid Pathways That Influence Alzheimer’s Progression
3
Symbravo Offers Multi-Mechanistic Option for Patients With Unmet Migraine Needs
4
Striking the Balance: Evidence-Based versus Defensive Medicine
5
















































































































































































































